AR121911A1 - Forma cristalina de compuesto bloqueador de fugas vasculares - Google Patents

Forma cristalina de compuesto bloqueador de fugas vasculares

Info

Publication number
AR121911A1
AR121911A1 ARP210101079A ARP210101079A AR121911A1 AR 121911 A1 AR121911 A1 AR 121911A1 AR P210101079 A ARP210101079 A AR P210101079A AR P210101079 A ARP210101079 A AR P210101079A AR 121911 A1 AR121911 A1 AR 121911A1
Authority
AR
Argentina
Prior art keywords
crystalline form
vascular leak
blocking compound
stability
blocker
Prior art date
Application number
ARP210101079A
Other languages
English (en)
Inventor
Koo Hyeon Ahn
Myung Kim
- Pyo Jung Hwa
- Baek Chul Su In
Sung Hwan Kim
Original Assignee
Curacle Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curacle Co Ltd filed Critical Curacle Co Ltd
Publication of AR121911A1 publication Critical patent/AR121911A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J67/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of two rings, each by one atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J17/005—Glycosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una forma cristalina de 6-((3S,8S,9S,10R,13S,14S,17R)-3-(((5S,6R)-5-acetoxi-6-(acetoximetil)-5,6-dihidro-2H-piran-2-il)oxi)-10,13-dimetil-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahidro-1H-ciclopenta[a]fenantreno-17-il)hept-5-enoato de (E)-metilo y un bloqueador de fugas de vasos sanguíneos que comprende la misma. La forma cristalina novedosa tiene alta pureza, excelente estabilidad, excelente almacenamiento a largo plazo y estabilidad farmacéutica, y puede usarse como bloqueador de fugas vasculares, por lo que es muy ventajoso para la producción de principio activo de alta calidad.
ARP210101079A 2020-05-04 2021-04-22 Forma cristalina de compuesto bloqueador de fugas vasculares AR121911A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020200053232A KR102223276B1 (ko) 2020-05-04 2020-05-04 혈관 누출 차단제 화합물의 신규 결정형

Publications (1)

Publication Number Publication Date
AR121911A1 true AR121911A1 (es) 2022-07-20

Family

ID=75163899

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101079A AR121911A1 (es) 2020-05-04 2021-04-22 Forma cristalina de compuesto bloqueador de fugas vasculares

Country Status (4)

Country Link
KR (1) KR102223276B1 (es)
AR (1) AR121911A1 (es)
AU (1) AU2020442000B2 (es)
WO (1) WO2021225233A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102124470B1 (ko) * 2019-12-13 2020-06-18 주식회사 큐라클 신규 혈관누출 차단제의 고수율 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102656153B (zh) * 2009-10-29 2015-02-18 延世大学校产学协力团 新型血管渗漏阻断剂
KR101481709B1 (ko) * 2014-01-03 2015-02-02 인하대학교 산학협력단 Ｓａｃ－１００４ 복합체를 유효성분으로 포함하는 발기부전 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
AU2020442000A1 (en) 2021-11-18
AU2020442000B2 (en) 2022-08-25
KR102223276B1 (ko) 2021-03-05
WO2021225233A1 (ko) 2021-11-11

Similar Documents

Publication Publication Date Title
AR121911A1 (es) Forma cristalina de compuesto bloqueador de fugas vasculares
USRE28819E (en) Dialkylated glycol compositions and medicament preparations containing same
ES2566800T3 (es) Nitrooxiderivados de prostaglandinas
TW200536542A (en) Regiospecific synthesis of rapamycin 42-ester derivatives
JP2013503206A (ja) マイクロ針を用いた局所及び経皮投与におけるカンナビジオールプロドラッグの使用
EP3233105B1 (en) Novel combination and use
ES2263853T3 (es) Uso de prostaglandina a o sus derivados para el tratamiento de la psoriasis.
AR123570A1 (es) Tratamientos para el edema macular diabético y la agudeza visual disminuida
US20100272783A1 (en) Methods of Treating Infections of the Nail
ES2457519T3 (es) Pasta a base de agua que contiene diclofenaco sódico
US7820652B2 (en) Regimen for the administration of rifamycin-class antibiotics
PE20010636A1 (es) Composiciones de agentes activos poco solubles como ciclosporina, paclitaxel o nifedipina para administracion oral o topica
EP3377512A1 (en) Nucleic acid prodrugs
ES2963437T3 (es) Compuesto de aminoalquilo
ES2858431T3 (es) Purificación de pleuromutilina
DK173552B1 (da) Anvendelse af prostaglandin-E1-derivater til fremstilling af farmaceutiske præparater til transkutan indgift
CN108367007A (zh) 用于伤口的治疗剂
WO2016170489A4 (en) Pharmaceutical compositions of proteasome inhibitor
BR112021020382A2 (pt) Forma cristalina de composto bloqueador de vazamento vascular
RU2014149705A (ru) Производные стеринов и их применение для лечения заболеваний, связанных с трансформированными астроцитными клетками, или для лечения злокачественных заболеваний крови
US10328063B2 (en) Method of wound healing
ES2262459T1 (es) Nuevas formas cristalinas de atorvastatina semicalcica y procedimientos para su preparacion.
RU2011148301A (ru) Способ синтеза производного эфира и глицирретиновой кислоты и соединение сложного эфира дезоксиглицирретиновой кислоты
WO2016135037A1 (en) Dianhydrohexitol codrug
MX2023011464A (es) Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7).